Flubromazepam Pellets - 8mg
Flubromazepam Pellets - 8mg Price range: € 15,00 through € 200,00
Back to products
Dechloroetizolam Pellets 5mg compressed thienotriazolodiazepine research pellets
Dechloroetizolam Pellets - 5mg Price range: € 15,00 through € 200,00

Flubrotizolam (FANAX) – 0.5mg

Price range: € 19,00 through € 312,50

Flubrotizolam (FANAX) 0.5mg Pellets are described as compressed research pellets containing a nominal 0.5 mg of flubrotizolam per unit.

Flubrotizolam is a thienotriazolodiazepine-related compound structurally associated with the benzodiazepine class.

The supplied specifications identify FANAX and JYI-73 as synonyms and report CAS number 57801-95-3, molecular formula C17H12BrFN4S, and molecular weight 419.28 g/mol.

The supplied molecular formula calculates to approximately 403.28 g/mol. The chemical identity and CAS assignment require independent verification.

The source claims ingredient purity of at least 98%, third-party analytical testing, batch traceability, and content uniformity below 3% RSD.

No actual batch-specific Certificate of Analysis, finished-pellet assay, or content-uniformity dataset was supplied.

The nominal 0.5 mg label claim should not be treated as an independently verified quantitative measurement.

Flubrotizolam is associated with benzodiazepine-related hazards, including profound sedation, impaired coordination, dependence, and potentially dangerous interactions with other central nervous system depressants.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-12478 Category:
Description

Flubrotizolam (FANAX) 0.5mg Pellets – Research Material Information

Flubrotizolam (FANAX) 0.5mg Pellets – Product Overview

Flubrotizolam (FANAX) 0.5mg Pellets is the supplied catalog designation for compressed research pellets described as containing flubrotizolam.

The source specifies a nominal ingredient content of 0.5 mg per pellet.

This figure represents a label claim, not a verified finished-pellet assay.

The source places the material within laboratory contexts involving thienotriazolodiazepine chemical identity, structural characterization, and analytical documentation.

No actual batch-specific Certificate of Analysis, finished-pellet content report, or independent laboratory record was supplied.

The material is not established as a certified reference standard or approved pharmaceutical product.

Chemical Identity & Classification

Flubrotizolam is described as a fluorinated and brominated thienotriazolodiazepine-related compound.

The source provides the following specifications:

  • Reported chemical name: Flubrotizolam
  • Supplied synonyms: FANAX, JYI-73
  • Reported CAS number: 57801-95-3
  • Supplied molecular formula: C17H12BrFN4S
  • Supplied molecular weight: 419.28 g/mol
  • Reported form: Compressed pellets
  • Nominal ingredient content: 0.5 mg per pellet
  • Intended designation: Research Use Only

The supplied molecular formula calculates to approximately 403.28 g/mol rather than the reported 419.28 g/mol.

The reported CAS number also differs from the number provided in another supplied flubrotizolam product description.

The correct structural assignment, CAS number, synonyms, and molecular specifications require verification before definitive publication.

Public chemical-reference information can be reviewed through PubChem, ensuring that any selected record corresponds to the exact intended compound.

Chemical & Physical Characteristics

The source describes compressed pellets containing flubrotizolam.

No actual product inspection record, pellet dimensions, hardness measurements, or disintegration data were supplied.

The source does not identify the excipients or establish the physical state of the ingredient within the pellet matrix.

Solubility, thermal stability, and quantitative recovery are mentioned as analytical considerations.

However, no validated finished-product measurements were provided.

The nominal pellet content does not establish reproducible sub-microgram transfers or quantitative analytical recovery.

The pellet format alone does not demonstrate consistent dissolution or uniform ingredient distribution.

Purity & Analytical Verification

The source claims ingredient purity of at least 98% by HPLC.

It also refers to HPLC, LC-MS/MS, and NMR spectroscopy for identity confirmation.

No chromatogram, mass spectrum, NMR spectrum, impurity report, or batch-specific Certificate of Analysis was supplied.

The claimed purity therefore remains unverified.

Ingredient purity and finished-pellet content are distinct measurements.

A high-purity ingredient does not establish that each pellet contains exactly 0.5 mg of flubrotizolam.

The source describes ultra-trace analytical contexts, but no validated quantitative reference value or certified reference-material documentation was supplied.

The pellets should not be described as certified analytical standards without appropriate supporting records.

Quality Control & Batch Integrity

The source claims third-party laboratory testing, ISO/IEC 17025 accreditation, batch traceability, controlled manufacturing, and finished-pellet content uniformity below 3% RSD.

These claims are not supported by supplied batch-specific documentation.

No finished-pellet assay, content-uniformity dataset, laboratory accreditation record, manufacturing record, or independent laboratory report was provided.

Pellet weight, ingredient purity, and actual ingredient content are distinct properties.

A consistent total pellet mass does not independently establish uniform flubrotizolam content.

The Research Use Only designation does not demonstrate certified quality or validated analytical performance.

Safety, Handling & Laboratory Precautions

Flubrotizolam is a benzodiazepine-related compound associated with central nervous system depressant hazards.

Potential risks include profound sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.

Combining benzodiazepine-related substances with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.

The source does not provide a verified product-specific Safety Data Sheet.

Institutional safety procedures should address restricted access, appropriate protective equipment, secure custody, accidental-exposure response, contamination prevention, and waste management.

The pellet presentation does not imply suitability for human or animal administration.

Packaging, Labeling & Storage

The source describes compressed pellets supplied in resealable packaging.

No actual container specification, packaging-validation record, or finished-product stability study was supplied.

The source recommends storage at approximately -20°C in a dry environment protected from light and moisture.

No validated stability data were provided to establish that temperature as a confirmed storage requirement.

The source does not establish a verified shelf life or long-term protection against environmental degradation.

Inventory records should distinguish nominal label claims from verified batch information.

Intended Research Use & Market Positioning

The source places flubrotizolam within laboratory contexts involving thienotriazolodiazepine chemical identity, analytical characterization, and structural comparison.

No certified reference-material status or validated quantitative performance has been demonstrated.

The supplied Raw Lab Chems catalog references include Flubromazepam Pure, Flubromazepam Powder, and Flubrotizolam FANAX Bars.

These listings describe different compounds or product presentations.

Their chemical identity, formulation equivalence, ingredient purity, and finished-product analytical performance have not been independently established.

The supplied links do not identify a dedicated product page for the 0.5 mg pellet presentation.

Catalog relationships should not be interpreted as evidence of interchangeable formulations or certified analytical status.

Ordering, Availability & Fulfillment

The source claims international shipping, temperature-controlled transport, tracking, and customs documentation.

No current inventory information, carrier authorization, shipment documentation, or verified delivery information was supplied.

The source also characterizes the material as a Schedule I research chemical and claims IATA/DOT compliance.

Neither the asserted scheduling classification nor the transport-compliance claim has been independently verified.

Controlled-substance classifications depend on jurisdiction and should not be generalized.

Research-only labeling does not establish a legal exemption.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Flubrotizolam is a benzodiazepine-related compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.

Institutions remain responsible for determining applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.

No therapeutic approval, consumer-use authorization, or certified analytical status is implied.

Additional information
Quantity (pellets)

10

,

25

,

50

,

100

,

250

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Flubrotizolam (FANAX) – 0.5mg”
Shipping & Delivery